Conmed (NASDAQ: CNMD) reported Q4 EPS of $0.90, $0.01 better than the analyst estimate of $0.89. Revenue for the quarter came in at $264.9 million versus the consensus estimate of $265.57 million.

“2019 was an exciting year for CONMED,” commented Curt R. Hartman, CONMED’s President and Chief Executive Officer. “We introduced a broad range of innovative new products and completed the successful integration of the Buffalo Filter acquisition. We exited the year by increasing our investment in our sales organization during the fourth quarter as planned, further strengthening our foundation for sustainable near- and long-term revenue and profitability growth. I am proud of what the team accomplished in 2019, and I look forward to building on this momentum in 2020.”

GUIDANCE:

Conmed sees FY2020 EPS of $3.08-$3.13, versus the consensus of $3.03.

For earnings history and earnings-related data on Conmed (CNMD) click here.